European Guidelines for Workplace Drug Testing in UrineandOral fluid

Similar documents
European Guidelines for Workplace Drug Testing in Blood and Blood Spots

DOF. Scheme Description. Drugs in Oral Fluid Scheme

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

Drugs of Abuse I Serum

DAU. Scheme Description. Drugs of Abuse in Urine Proficiency Testing Scheme

The Drug Testing Process. Employer or Practice

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

European Guidelines for Workplace Drug and Alcohol Testing in Hair

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

LABORATORY TECHNICAL SPECIFICATIONS MANUAL

LABORATORY TECHNICAL SPECIFICATIONS MANUAL

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

INTERPATH LABORATORY, INC. TEST UPDATES

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

POINT OF CARE TESTING

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

LABORATORY TECHNICAL SPECIFICATIONS MANUAL

Schedule of Accreditation

Laboratory Service Report

Urine Opioid Dependency Panel (UODP) 1

LC Application Note. Dangerous driver?

Welcome - SAMHSA s Role. Welcome SAMHSA Key Messages 4. Welcome SAMHSA s Direction

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography

Lyndsey Knoy, D-ABFT-FT Forensic Scientist Washington State Toxicology Laboratory.

Urine drug testing it s not always crystal clear

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX

Cozart DDS Drug Detection System On-site Saliva Drug Testing

Applications of High Resolution Mass Spectrometry in Forensic Toxicology. Patrick Kyle, PhD.

DrugConfirm Advanced Urine Dip Cards.

Physician s Reference for Urine and Blood Drug Testing and Interpretation

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.

DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide.

Proof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples

DRUGS OF ABUSE

Forensic Toxicology Scope of Testing and Detection Limits

Drug & Alcohol Testing in. Canada. Point of Care Testing

TRIM reference DD17/ Endorsed by Publication date Review date

Urine Drug Testing Methods 3-5

Drug Adherence Assessment Report

CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva)

Pain Medication Management Program Monitors Patient Compliance

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

Driving Under The Influence Of Drugs In Ireland: A Growing And Significant Danger

Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey

Your Results are Our Priority.

Pain Medication Management Program Supports Patient Outcomes and Adherence

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.

Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature. Distributed to # of Copies Distributed to # of Copies

«Tit» «Name» «Fam_Nam» «Organization» «Address1» «Address_2» «PO_Box» «City». «Country» Sevilla, February, 2016

ChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016)

MEDICAL POLICY Drug Testing

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing

Testing for Controlled Substances

Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab

Urine Drug Screening: The Essentials of Interpretation

Drug Profiles of Apprehended Drivers in Victoria

Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids

Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1

Detection of Neonatal Drug Exposure Using Umbilical Cord Tissue and Liquid Chromatography Time-of-Flight Mass Spectrometry

MEDICAL POLICY Drug Testing

Fastect II Drug Screen Dipstick Test Training and Certification Program

URINE DRUG TOXICOLOGY

HSE National Drug Treatment Centre Drug Analysis Laboratory. A Guide to Service Users

Evaluation of an LC-MS/MS Research Method for the Analysis of 33 Benzodiazepines and their Metabolites

Guidelines for Human Urine Collection

nextgen precision Test Report

Welcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017

VIRGINIA DEPARTMENT OF HEALTH OFFICE OF THE CHIEF MEDICAL EXAMINER

HSE National Drug Treatment Centre Drug Analysis Laboratory. A Guide to Service Users

Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs

Contract No. 952-M1 Collection Service Requirements Texas Department of Criminal Justice (TDCJ)

E XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

T R A I N I N G G U I D E

Quest Diagnostics Drug Testing Index Full Year 2015 Tables

Opiates, Opioids and Benzodiazepines, Amphetamines & Illicit Drug Forensic Analysis by LC/MS

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY

Fast and easy separation of 23 drugs of abuse. including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS

Controlled Substance Monitoring in the Age of the Opioid Epidemic

INSTANT DRUG SCREENING

Procedure for Toxicology Analysis Version 7 Toxicology Unit Effective Date: 03/14/2014 Issued by Drug Chemistry Forensic Scientist Manager

Toxicology Testing Is it a Good Fit for Your Laboratory? Rebecca Kenner, BA, MT, DLM(ASCP) Leigh Ann Smith, BS, MLS(ASCP), CLS

Pinellas County Forensic Laboratory. Annual Report 2006

QuickTox Drug Screen Dipcard (with and without Adulteration Tests)

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

QuickTox Drug Screen Dipcard (with and without Adulteration Tests)

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.

Transcription:

EWDTS European Workplace Drug Testing Society European Guidelines for Workplace Drug Testing in UrineandOral fluid 9th EWDTS Symposium in Lisbon Sanna Taskinen Michaela Neuhofer

Updating project # 2 Current old versions of the guidelines: Guidelines for Urine (2002) Drug and Alcohol Testing in Hair, Collection and Analysis (2010) Guidelines for Oral fluid (2011) Specimen Collection Guidelines (2011)

Updating project # 3 January 2014: chairs of the project were settled Urine guideline (chair: Sanna Taskinen) Oral fluid guideline (chair: Michaela Neuhofer) Hair guideline (chair: Alberto Salomone) Blood/blood spots (chair: Wim Schielen) The experts were chosen for the committee Meeting in Frankfurt 26th November, 2014 Approval of the board: April, 2015

The Guidelines Committee for Urine and Oral fluid # 4 Beck, Olof(Sweden) Bosch, Tessa (Netherlands) Böttcher, Michael (Germany) Carmichael, Duncan (UK) Fucci, Nadia (Italy) George, Claire (UK) Neuhofer, Michaela (Austria) Piper, Mark (UK) Salomone, Alberto (Italy) Schielen, Wim (Netherlands) Steinmeyer, Stefan (Germany) Taskinen, Sanna (Finland) Weinmann, Wolfgang (Switzerland)

The Guidelines Committee for Urine and Oral fluid # 5 1. General 2. Definitions 3. Collection 4. Laboratory Organisation 5. Laboratory Analysis Procedures 6. Analytical Methods and Validation 7. Quality Assurance and Quality Control 8. Interpretation of Results 9. Challenges to Drug Test Results Appendix A: Collection Procedure Appendix B: Donor s statement of Informed Consent Appendix C: Fatal flaws in the Chain of Custody Appendix D: Cut-off values for Screening Tests Appendix E: Cut-off values for Confirmation Tests

Main content and/or changes Urine and Oral fluid # 6 Chapter 1: General Requirement of accreditation (EN ISO/IEC 17025 and/or EN ISO 15189) Guidelines are relevant to laboratory-based testing only Chapter 2: Definitions Identical to make the guidelines more comparable Make sure that key-word are understandable for anybody Chapter 4: Laboratory Organisation All personnel should adhere to the requirements of EN ISO/IEC 17025 and/or EN ISO 15189 Minimum key functions for accreditation Descriptions of key functions are shortened

Main content and/or changes Urine and Oral fluid # 7 Chapter 6: Analytical Methods and Validation 6.1. Acceptable Screening Techniques Immunoassays chromatographic techniques 6.2 Laboratory Screening Tests The initial screening test must use an appropriate technique also chromatogaphic techniques. 6.4 Confirmation Tests By chromatograpic technique in combination with MS quantitativ If the first analysis is performed by a confirmation-level analysis (massspectrometry), the positive findings have to be confirmed and quantified by reanalysis with another portion of the sample. 6.5 Validation Parameters formethodevalidationarelisted: precision, cutoff verification, selectivity, limitofdetection, limitofquantification, sensitivity, specificity, stability, measurement uncertainty, recovery of the collection device and matrix effects 6.7 Long termfrozenstorage(-20 o Corbelow) Date and location

Main content and/or changes Urine and Oral fluid # 8 Quality controls Preparation, use and storage of calibrators and controls more in detail. Chapter 7: Quality Assurance and Quality Control Chapter 8: Interpretation of Results Confirmation tests references: - ECguidance of quality control and validation procedures for pesticide analyses (2013) - ECdecisionconcerning the performance of analytical methods and the interpretation of results (2002) - Guideline of GTFCh Requirements of identification for chromatography and mass spectrometry more in detail. Toxicology Review: Toxicologists right to interpret results: if local legislation allows Medical Review: removed to this chapter from appendix.

Main content and/or changes in Urine # 9 Chapter 3: Collection Urine: Well establish procedure. In Appendix A more about exceptional situations. Appendix A Collection Procedure Chapter 5: Laboratory Analysis Procedures Urine Collection Procedure Collection site requirements more in detail Informing the donor about the test Equal treatment of donors Privacy(observed collection in certain circumstances) Exceptional situations and instructions added Chain of custody Reporting of preliminary presumptive positive results as local legislation allows. If the first analysis is performed by a confirmation-level analysis (mass spectrometry), the positive findings have to be retested with another portion of the sample. Urine validity testing: Unvalid samples: how to report negative/positive results more in detail

Main content and/or changes in Appendices # 10 Appendix B Example of a Donor s Statement of Informed Consent Added: I confirm that I have received information about the meaning and content of the drug test. Appendix C Some Examples of Fatal Flaws in the Chain of Custody No changes

Main content and/or changes in Oral fluid # 11 Chapter 3: Collection Oral fluidcollection Oralfluid collection kits: more reliable oral fluid collection which enables quantification of drug. This means that accurate determination of collected OF is strongly recommended (gravimetric analysis or spectro-photometrically) Oral fluid collection procedure: obligatory collection of identical sample A and sample B -must be carried out legal defensible and split sample in the presence of the donor or use two devices to generate two samples Appendix A Collection Procedere Oral Fluid Collection Procedere Note collection time Check the volume of oral fluid on/in the specimen collection device. Inspect the specimen to determine its colour and appearance of any signs of contaminants and adulteration.

Main content and/or changes in Oral fluid # 12 Chapter 5: Laboratory Analysis Procedures 5.3 Sample Receipt Laboratory should receive at least two sample container 5.4 Sample Processing Container A for the screening and confirmation test Sample B retain unopendand stored in condition that reflect the storage of the sample under test 5.5 Oral fluid validity testing: Laboratoryhas to expose adulteration and sample tampering Following data have to be coherent Collection time Dilution factor (gravimetrical analysis or measured spectrophotometrically) Sample volume Endogenous biomarker (e.g. salivary Amylase, Cortisol, )

APPENDIX D SCREENING CUT OFF ON MONDAYMORNING? What happend on Friday, last week or last month? Blood Under the influence of drug within 48 hours Oral fluid Short detection window within 48 (72) hours Urine Intermediate detection window within 72 hours (6 weeks) Hair Long detection window within months

APPENDIX D SCREENING CUT OFF ON MONDAYMORNING? Whathappend on Friday, last weekorlast month? Oral fluid - Short detection window Core Panel / Optional / Under investigation CORE PANEL Amphetamine group 40 Cannabis (THC) + metabolites 10 Cocaine + metabolites 30 Opiates (Morphine) 40 6-AM 4 Methadone (l) 50 Benzodiazepines group 10 OPTIONAL Buprenorphine 5 Propoxyphene or metabolites 40 Cut off under discussion e.g. Pregabaline, Synthetic cannabinoids, Synthetic cathinones(mdpv etc.), Z-Drugs(Zopiclon, Zolpidem, Zaleplon)

APPENDIX D URINE SCREENING Urine Intermediate detection window CORE PANEL Amphetamine group 500 Benzodiazepines group 200 Cannabis metabolites 50 Cocaine metabolites 150 Opiates(total) 300 EDDP(or methadone) 100 (300) OPTIONAL Barbiturates 200 Buprenorphine 5 LSD or metabolites 1 Phencyclidine 25 Propoxypheneormetabolites 300 OTHER DRUGS Cut-off under investigation/discussion Gammahydroxybuturate(GHB) Ketamine Other opioids (at least oxycodone, hydromorphone, tramadol, fentanyl, tilidine) Pregabaline Synthetic cannabinoids Synthetic cathinones(mdpv etc.) Z-Drugs(Zopiclon, Zolpidem, Zaleplon)

APPENDIX E CONFIRMATION CUT OFF ON MONDAYMORNING? What happend on Friday, last week or last month? Blood Under the influence of drug within 48 hours Oral fluid Short detection window within 48 (72) hours Urine Intermediate detection window within 72 hours (6 weeks) Hair Long detection window within months

APPENDIX E ORAL FLUID CONFIRMATION AMPHETAMINE Amphetamine (d+ l) 30 Methamphetamine 30 MDA 30 MDMA 30 Other members of the amphetamine group CANNABIS(THC) 2 COCAINE Cocaine metabolite (Benzoylecgonine) Cocaine 8 Cocaethylene 8 BENZODIAZEPINE 7-Amino-flunitrazepam 10 7-Amino-clonazepam 10 7-Amino-nitrazepam 10 Alprazolam 10 Bromazepam 10 Clonazepam 10 Desmethyldiazepam 10 Diazepam 10 Flunitrzepam 10 Flurazepam 10 Lorazepam 10 Lormetazepam 10 Midazolam 10 Nitrazepam 10 Nordiazepam 10 Oxazepam 10 Phenazepam 10 Temazepam 10

APPENDIX E ORAL FLUID CONFIRMATION METHADONE Methadone or metabolites(d+l) 20 EDDP OPIATES Morphine 2 Codeine 2 Norcodeine 2 6-Acetylcodeine 2 Dihydrocodeine 2 6-Monoacetylmorphine 4 cut off under investigation/ discussion: Buprenorphine or metabolites Propoxyphene or metabolites Ketamine LSD or metabolites Opioids( at least Oxycodone, Hydromorphone, Tramadol, Buprenorphine, Fentanyl, Tilidine) Phencyclidin(PCP) Pregabaline Synthetic cannabinoids Synthetic cathinones(mdpv etc.) Zaleplon Zolpidem Zopiclone

APPENDIX E URINE CONFIRMATION AMPHETAMINES (should include but not limited to:) Amphetamine (d+ l), Metamphetamine, MDA, MDMA 200 Other members of the amphetamine group 200 BENZODIAZEPINES (or metabolites) (should include but not limited to:) Alprazolam,Bromazepam, Clonazepam, Diazepam, Flunitrzepam, Flurazepam, Lorazepam, Lormetazepam, Midazolam, Nitrazepam, Nordiazepam, Oxazepam, Phenazepam, Temazepam OPIATES (should include but not limited to:) 100 Morphine, Codeine, dihydrocodeine 300 6-Monoacetylmorphine 10 CANNABIS Cannabis metabolite(thc-cooh) 15 COCAINE Benzoylecgonine 150 METHADONE Methadone(d+l) 250 EDDP 100

OPTIONAL: APPENDIX E URINE CONFIRMATION Barbiturates 250 Buprenorphine or metabolite 2 LSD or metabolites 1 Phencyclidine 25 Propoxyphene or metabolites 300 OTHER DRUGS Cut-off under investigation/discussion Gammahydroxybuturate(GHB) Ketamine Other opioids (at least oxycodone, hydromorphone, tramadol, fentanyl, tilidine) Pregabaline Synthetic cannabinoids Synthetic cathinones(mdpv etc.) Z-Drugs(Zopiclon, Zolpidem, Zaleplon)

NEXT STEPS These guidelines are approved by the board. The guidelines will be now communicated within the members of EWDTS for feedback Please give comments on three levels: 1. It would be better if you change... including change in the language. 2. I strongly recommend this/these changes... 3. If you do not change this/these, I think the guidelines are unacceptable.

IN THEFUTURE The updating project will continue e.g. Cut-off values New substances New guidelines? Guideline for alcohol? Guideline for POC-testing? Guideline for MRO? Guideline for breath air?

Thank you for your attention! Guidelinescommitteemeetingin Frankfurt 26 th November, 2014